Anjarium Biosciences AG

Swiss Biotech Association

Member

At Anjarium we are advancing our Hybridosome™ technology to leverage unmatched advantages in the realm of engineering extracellular vesicles (incl. exosomes) to act as smart carriers and to maximize the therapeutic potential of naturally occurring vesicles.

Location

Wagistrasse 25/27, Schlieren, Switzerland

Get Directions

Facts & figures

Type of organization

Private company
Year of foundation

2016
Number of employees in Switzerland

1-9

Key business

Core competencies

Platform technologies

You may also be interested in

GlycoEra AG

GlycoEra leverages its control over natural glycan-mediated pathways to advance novel drugs using its propriety platform, the CustumGlycan Platform. GlycoEra develops first in class therapeutics in inflammatory disease, autoimmune disorder and immuno-oncology indications.
8952 Schlieren

Member

cellvie AG

cellvie is pioneering Therapeutic Mitochondria Transfer, a novel treatment approach aimed at the cellular energy metabolism. The technology's first application will be in ischemia-reperfusion injury, specifically in kidney transplantation. But the aim is to develop a broad platform.
9548 Matzingen

Member

Linkster Therapeutics AG

Linkster Therapeutics AG develops novel therapeutic antibodies using our proprietary Flycode® and Sybody® platforms. Our technologies screen antibody properties in high throughput <em>in vivo</em>, thus enabling precise tissue targeting beyond trivial molecular recognition and massively reduce animal trials.
8006 Zürich

Member